Skip to content
Homepage
Author:
Xeltis
Posted Date:
July 2, 2026
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
Xeltis
July 2, 2026
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
Xeltis
April 21, 2026
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization
Xeltis
April 21, 2026
